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Stem cell therapy (SCT) has shown very promising preclinical results in a variety of regenerative medicine applications.
Nevertheless, the complete utility of this technology remains unrealized. Imaging is a potent tool used in multiple stages of SCT
and this review describes the role that imaging plays in cell harvest, cell purification, and cell implantation, as well as a discussion
of how imaging can be used to assess outcome in SCT. We close with some perspective on potential growth in the field.
1. Introduction
Stem cells and SCT have remarkable potential in develop-
mental biology, drug discovery, and regenerative medicine
[1–6], and imaging techniques are often employed to evaluate
the purity, state of differentiation, number, and location of
these cells. Stem cells have garnered increasing attention
because of their capacity to differentiate into diverse tissue
types and increase functional recovery. Stem cell types
include embryonic stem cells (ESCs) from the blastocyst,
mesenchymal stem cells (MSCs) and bone marrow stem cells
(BMSCs) harvested from adults, and induced pluripotent
stem cells (iPSC) that are reprogrammed from adult cells via
specific transfection factors [7]. Stem cell imaging provides
important information about the behavior and function of
stem cells including their location, protein expression levels,
viability and percent viability, and differentiation status, as
well as interactions between the cells and the adjacent tissue
[8]. A general outline of stem cell imaging is shown in
Figure 1—this in turn is an outline for the rest of this paper.
We review the state of the art in functional and anatomic
imaging in SCT and regenerative medicine. We highlight the
role that imaging plays in stem cell selection and delivery as
well as during therapy and for posttreatment validation.
2. Stem Cell Preparation
SCT starts with cell preparation, cell labeling, and cell sorting.
For example, MSCs must be purified from the bone marrow
aspirate, expanded, and labeled. After labeling, cells are
sorted to optimize the contrast signal, remove dead or dying
cells, and select a population that is positive for the exogenous
label or stably expressing the reporter gene. Throughout this
section, we will characterize the labeling methods used for
cells as either direct or indirect. Most simply, direct imaging
uses exogenous labels and indirect imaging transfects cells
with reporter genes [9].The principle and procedure of direct
and indirect labeling methods are shown in Figure 2.
2.1. Direct versus Indirect Labeling. In direct labeling in SCT,
small molecules such as fluorophores, radioisotopes, and
nanoparticles are added to the cells during expansion in tissue
culture.The labels can be on the cell surface or the cell interior
(Figure 2(a)), although confining the labels to intracellular
compartments is usually preferred. This is because labels
on the exterior could potentially become dislodged and
contribute to background signal. Transfection reagents may
be used to increase the efficiency of label uptake.
Paramagnetic nanoparticles and lipophilic fluorophores
are common contrast agent of direct imaging for mag-
netic resonance imaging (MRI) and optical imaging, respec-
tively. Probes used for radionuclide imaging include flu-
orodeoxyglucose (18F-FDG) and 111In oxine. A complete
discussion of all types of direct cell labels is beyond the
scope of this paper and the interested reader is referred to
reviews dedicated to that topic [10]. The advantages of direct
labeling include its simplicity, precise amount of control of
label concentration and formulation, and short processing
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Figure 1: Procedure for SCT. Cells can be labeled with contrast agent either directly or indirectly.The labeled cells are purified from unlabeled
cells to obtain a cell product with high signal and thus contrast versus adjacent tissue. Before the delivery, the stability of the labeled cells can
be tested to assess any potential toxicity of the imaging agent. After delivery, the viability of the delivered cells is monitored to understand
engraftment and survival. The labeled stem cells can be clearly recognized due to increased signal produced by the label. Finally, histology
and associated microscopy techniques can confirm that the imaging signal does indeed correspond to the cells of interest.
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Figure 2: Labeling approaches used in SCT. (a) Direct labeling combines ((a)-(i)) cells and contrast agent andmay use a transfection agent to
increase the amount of agent that crosses the cell membrane. ((a)-(ii)) The labeled cells are selected from primary cells and are then injected
into the target area. ((a)-(iii)) Because the label diffuses as the cells divide, contrast signal will decrease as time passed. (b) In indirect labeling,
((b)-(i)) the cells’ genome is modified by reporter gene that encodes for receptors, fluorescent proteins, or enzymes. Except for fluorescent
reporter protein, the reporter gene usually does not generate contrast signal itself, but is responsible for the activation of a contrast agent that
is added at the time of imaging. ((b)-(ii)) Unlike direct labeling, constitutively expressing genes gene will be copied to daughter cells and the
expanded cells can be imaged as well. Reproduced courtesy of Nature Publishing Group [7].
times [8, 9]. However, its applications are limited temporally
because the label concentration decreases by roughly one-half
in the daughter cells upon every cell division. This decreases
the signal as a function of time. Another challenge specific
to radionuclide-based imaging is decay of the direct label
such as 111In oxine [11]. Additionally, direct labeling rarely
provides information of the cells’ viability and proliferation—
that is, the signal is always “on.”This is true even after the cell
has died—labels not connected to cells can be misconstrued
to be viable cells although direct labels from dead cells are
likely scavenging by macrophages or removed via systemic
circulation. These disadvantages limit the use of direct labels
for the long-term tracking of labeled cells.
Indirect labeling introduces a reporter gene into the
genome of the cell of interest to express receptors, enzymes,
or fluorescent/bioluminescent proteins suitable for imaging
cell location, number, function, and so forth (Figure 2(b))
[12].These gene products are responsible for either generating
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contrast signal (e.g., fluorescent green protein for optical
imaging) or participating in the reaction with exogenous
labels for signal generation (e.g., herpes simplex virus type
1 thymidine kinase (HSV1-tk) for positron emission tomog-
raphy (PET) or luciferase/luciferin reaction for biolumi-
nescence). Thus, the mechanism of contrast is encoded in
the cells’ genome with expression being inherited to daughter
cells—the amount of signal should be proportional to the cell
number. In constitutively expressing cells there should be no
decrease in signal intensity between generations [9]. Tran-
sient reporter genes may show reduced expression within a
single generation or across generations due to silencing of
the exogenous reporter gene by the host genome—this is
especially common when retroviruses are used to transfect
the stem cells [13].
There are also many potential risks that have limited
the widespread use of indirect labeling in SCT. Indeed, this
approach requires the genome to be altered and often needs
viral vectors to facilitate transfection or may need gene
silencing [9]. Therefore, indirect imaging is generally only
approved in terminally ill patients [14]. Nevertheless, more
precise integration of reporter genes into the PPP1R12C locus
via zinc finger nucleases shows both high pluripotency and
long-term gene expression even in differentiated progeny
[15].
2.2. Sorting and Purification of Labeled Cells. Neither direct
nor indirect SCT labeling can guarantee 100% labeling yield.
The labeling efficiency is determined by the surface properties
and dose of contrast agents, cell type, membrane coating of
the cells, incubation time, and the presence of transfection
factor [16–19]. Some direct labels facilitate a calculation of
loading efficiency.These cells populations can also be purified
to increase the percentage of labeled cells. This is easily
done with tags with a fluorescent signal such as dual mode
iron oxides or other nanoparticles [18, 20]. Purification is
more challenging with radionuclide probes. Fluorescence-
activated cell sorting (FACS) is commonly used in sorting
cells.This can use the fluorescent signal of an exogenous label
or signal from GFP in a reporter gene. Once the equipment
recognizes a fluorescent signal, the cells are charged and
separated in an external electrical field. Reporter genes such
as those transfected by HSV-1tk cannot be easily recognized,
and thus a GFP gene is usually added on the same construct
as the reporter to guide in FACS sorting [21]. Similarly,
cells containing fluorescently labeled magnetic nanoparticles
(MRI contrast agent) can be sorted in FACS. Furthermore,
magnetically assisted cell sorting (MACS) is an alternative
for sorting magnetic particles for MRI [22]. MACS separates
magnetic particles in a high gradient magnetic column [23].
However,MACSmay also collectmagnetic nanoparticles that
are not bound to cells—these redundant nanoparticles result
in high background.
2.3. Characterizing the Labels’ Cytotoxicity. The toxicity of
contrast agents must be evaluated before using them for SCT.
It is generally true that the more concentrated the label is,
the higher the contrast signal will be. However, everything,
evenwater, has a toxic dose. An optimal dose of contrast agent
should give satisfactory signal and no adverse effects. In the
remainder of this section we will describe (1) what factors
cause toxicity; (2) how to measure the toxicity; and (3) what
the safe dose of contrast agents is.
A label’s toxicity depends on various factors including the
label material, conjugated ligands or coating, concentration,
and the corresponding cell type. One of the main toxic
mechanisms of fluorophores is their accumulation in the
mitochondria, which disturbs the metabolism of the cell.
For example, indocyanine green (ICG) accumulates inside
cells resulting in a reduction of the dehydrogenase activity
and oxygen consumption in the mitochondria [24, 25]. The
toxicity of gold nanoparticles (AuNPs) can be attributed
to the formation of reactive oxygen species (ROS) and
the intracellular nanoparticle concentration [8]. Cationically
functionalized AuNPs cause moderate toxicity, and different
ligands cause specific toxicity [26]. Additionally, the remain-
ing surfactant used to grow gold nanorods is also toxic
because it is a detergent [27]. In addition, direct labels such
as nanoparticles can also perturb downstream cell function.
One example of this is altered expression of cytokines in
the presence of an exogenous label [28, 29]. A careful and
complete analysis of cell toxicity is needed for each novel label
type.
Radioisotopes are contrast agents used in nuclear imag-
ing such as single-photon emission computed tomography
(SPECT) andPET.Although some radioisotopes and reporter
genes for nuclear imaging have been demonstrated to be safe
in stem cells [30], using a dosage too high can induce obvious
reduction of proliferative activities of stem cells, indicating
presence of structural and genetic damage [31]. In addition,
excessive auger electrons (a type of electrons emission that
occurs when energy between other electron transitions was
transferred to the electrons) near the nucleus can cause
DNA double bond breaks in stem cells [32]. However, this is
relatively rare and is unique to auger emitters for radionuclide
therapy [33] and not more typical radionuclides. For MRI,
the toxicity of iron oxide nanoparticles is attributed to the
generation of ROS [34]. Although the toxicity of the contrast
agents varies, it may not always cause cell death. Measuring
cell viability is one way to determine the cytotoxicity.
The measurement of cell viability is a straightforward
method to determine the cell’s behavior and activity as well
as to assess the cytotoxicity of external labels. Several toxicity
assays based on different mechanisms have been developed
to measure the live cell number. Trypan blue exclusion is
a cheap method to determine viability and total cell counts
of cells. Once the cells are dead, their cell membranes lose
the ability to screen uptake from the surrounding environ-
ment and become blue [35]. Consequently, live cells only
have blue rims while dead cells are stained blue, and the
number of live cells can be determined. The MTT assay
is another assay that uses 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), a tetrazolium dye, to
measure the level of the cell’s metabolic activity. MTT can
crystalize in the presence of oxidative reduction to give a
color change from yellow to blue. The crystals are dissolved
in organic solvent and have peak absorption between 570 nm
and 590 nm [35]. The absorption is proportional to the cell
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numbers. Thus, it is a method to compare the viability and
proliferation of stem cells with and without contrast agents.
Another method to quantify stem cells’ viability is using
the resazurin assay. Resazurin is reduced to the fluorescent
resorufin by nicotinamide adenine dinucleotide (NADH)
or other reductive enzymes. This degree of reduction is
proportional to number of viable cells. This assay is highly
sensitive and dependent on the cell type, and the viability
and proliferation of stem cells can be estimated by measuring
their fluorescence [35].The 2󸀠-7󸀠-dichlorodihydrofluorescein
diacetate (DCFH-DA) assay is an intracellular probe for
measuring the oxidative stress generated by ROS. Under
oxidation, DCFH-DA generates DCF and fluorescence [36].
In other words, in the redox state the amount of ROS can
be measured by detecting the intensity of the fluorescence
[36]. Alternative schemes such as the detection of lactate
dehydrogenase (LDH) are reported [35].
Although the optimal dose for each contrast agent has
yet to be determined, some papers have described contrast
agent doses that simultaneously have good contrast signal
and cause low cytotoxicity. For example, the lipophilic flu-
orescent tracer DiD was safe to MSCs at 5 pM per cell [37].
Distinct SPECT images were obtained at a concentration of
1.9 pCi/cell even though 0.27 nCi/cell of 111In oxine incubated
in human MSCs (hMSCs) for 20 minutes and no adverse
effects were found in the cells [31]. For radioactive con-
trast agents, 6mCi of technetium-99m (99mTc)-exametazime
(HMPAO) in 10 million stromal vascular fraction cells
(SVFCs) showed negligible cytotoxicity and genetic damage
for sufficient SPECT/CT signal [38]; 64Cu-TETA-CD45 and
89Zr-CD45 immunoconjugates have negligible toxic effects
on the engraftedhumanperipheral blood stemcells (hPBSCs)
under 40 𝜇Ci/mL [39].
AuNPs are relatively inert but have shown some size-
dependent toxicity. In one study, the upper limit dose is 1012
particles per mL for 3 to 5 nm AuNPs [40]. Bare super-
paramagnetic iron oxide nanoparticles (SPIONs) show rel-
atively strong toxicity. For example, a concentration of
2mg/mL can cause a 60% decrease in the fibroblasts’ via-
bility [41]. But the coated SPION can stably exist in cells.
Labeling cells with dextran-coated SPION [42], chitosan
[43], polyethylene glycol (PEG 2K) [44], and alkyl-polycation
[45] at 30 𝜇g/mL, 80𝜇g/mL, 100 𝜇g/mL iron of SPION, and
7 𝜇g Fe/mL, respectively, shows negligible cytotoxic effects
and clear MR signal detection. Ultimately, every label has to
be studied because even slight differences can cause major
changes in toxicity profiles.
More sophisticated toxicity assays could be performed
to analyze characteristics of contrast agents in vivo because
labeling can influence protein expressions or differentiation
potentials of stem cells. For example, MSCs are able to dif-
ferentiate into osteogenic, adipogenic, and myocardial tissue.
Some articles have shown that using silica nanoparticles [29]
andPET radioisotopes [46] inMSCs has no obvious influence
ondifferentiation potential and proteomic contents. InMSCs,
fluc-mrfp-ttk triple fusion gene was found to cause certain
degree of alternations in differentiation, but the differentia-
tion potentials were preserved [47]. Similar analyseswere also
performed in ESCs when FLI/BLI/PET triple fusion genes
were applied [30].
After these in vitro toxicity assays are performed, the in
vivo pharmacokinetics, pharmacodynamics, absorption, dis-
tribution, metabolism, and excretion can be performed. This
is often accompanied by a dose escalation study including an
animal study in which a dose that is 100-fold higher than that
to be used in humans is given to animals on a weight/weight
basis. An excellent overview of the clinical translation process
is described in the literature [48].
3. Stem Cell Delivery
Delivering stem cells to the target tissue accurately, efficiently,
and effectively is a difficult issue that remains to be addressed.
Goals include (1) accurate delivery of cells in injured sites, (2)
avoiding damaging the host tissue, and (3) maintaining the
viability and the proliferation of stem cell after implantation
while avoiding the formation of malignancies such as ter-
atoma [49]. Based on the therapeutic application, the delivery
approach varies. Here, we introduce some delivery strategies
for SCT and some imaging methods that assist the delivery.
3.1. Delivery for Cardiac Therapy. SCT is a promising treat-
ment for cardiac disease, but tools to more accurately
deliver cells to the ischemic region could further improve
cardiac function. Approaches to deliver stem cells have
been comprehensively reviewed [50]. Although intravenous
injection is the easiest approach, it often results in low
delivery efficacy—only a small number of cells reach the
infarct region [51]. More straightforward alternatives include
threading a catheter into the coronary artery (intracoronary
transplantation) and direct injection into the cardiac muscle
(intramyocardial transplantation) shown in Figure 3 [51]. For
intracoronary applications, healthy cells are infused into the
infarct zone via a balloon catheter by pressure under percu-
taneous transluminal coronary angioplasty [51]. One concern
about intracoronary transplantation is that implantation into
the coronary artery may modulate blood flow in the already
damaged area of cardiac tissue. Furthermore, cell clusters or
cell fragments could potentially act as microemboli.
For endocardial applications, direct injection into car-
diac muscle either through the coronary sinus or coronary
artery uses a catheter-based injection system such as the
NOGA injection catheter [52]. Transendocardial transplan-
tation requires electromechanical mapping of the heart with
a diagnostic catheter and a deflectable tip [53]. Aftermapping,
a small gauge injection catheter and a core lumen transport
the cells to the myocardium at a stable slow rate [53]. One
limitation of transendocardial transplantation is that it might
also cause cell loss in the ventricle and during ventricular
arrhythmias [51]. For epicardial intramyocardial applications,
stem cells are directly injected to the myocardium outside of
the heart [54].
Although there are specific transplantation methods for
SCT, misinjection might also be responsible for the poor
therapeutic efficacy in SCT cardiac repair. To address this
issue, stem cell imaging can provide either static or dynamic
images of the implant event. Real-time imaging technologies
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Figure 3: Schematic of stem cell delivery methods for various SCT applications: in cardiac repair, stem cells are either delivered through
the vena cava or coronary artery for intracoronary application. Transcoronary sinus or transendocardial or direct injection is used for
intramyocardial applications. Reproduced courtesy of Elsevier Publishing group [51].
include ultrasound [55] and photoacoustic imaging [28, 56].
The contrast agent reports the number and location of the
stem cell and helps the physician accurately inject the cells
in the ischemic region. On the other hand, MRI is commonly
used to trace the implanted cells in cardiac infracts, but it can
only give information after the surgery.
3.2. Delivery for Retinal Therapy. Using stem cells to repair
nonfunctioning neuroretinal cells is promising, and the
delivery strategies have been improving. Direct injection
into the vitreous humor (intravitreal transplantation) and
direct injection into the retina (subretinal transplantation)
are the main delivery routes for retinal SCT [57]. Alternative
injection locations include the optic tract [58] and vein
[59]. Compared to subretinal transplantation, intraretinal
injection is easier and less invasive and results in higher
stem cell survival. However, intravitreal transplantation also
suffers from limited efficacy because of the migration barrier
between the vitreous cavity and the retina [60]. On the other
hand, stem cell transplantation through subretinal injection
has better delivery accuracy and higher cell differentiation,
but it is technically complicated [61].
Recently, subretinal delivery has been improved with
a biodegradable hydrogel-based delivery system that was
developed to implant stem cells to the subretina space and
results in an even cell distribution and high cell survival
rate [62]. The implantation can also be improved via an
ultrathin substrate platformwhich was developed to improve
the implantation of retinal pigment epithelium cells in the
subretinal space by reducing cell loss [63]. Both approaches
increase the safety, viability, and distribution uniformity of
subretinal transplantation. Furthermore, in both research
and clinical trial, optical coherence tomography has been
applied to trace the implanted cells [64] (NCT01773954, the
clinical trial registry number on clinicaltrials.gov).
3.3. Delivery for Spinal Cord Therapy. SCT is also used in
treating spinal cord injury (SCI). Transplantation of stem
cells in injured spinal cord can be performed through several
routes including systemic delivery [65] and direct intra-
parenchymal injection [66]. Systematic delivery includes i.v.
injection and intrathecal infusion (injection in subarachnoid
space). Both transplantation approaches require cells tomove
to the injury. Intraparenchymal transplantation injects cells
directly to the lesion.These threemethods have been compar-
atively studied in the delivery of neural stem/progenitor cells
into the injured spinal cord, and it was found that the repeated
intralesional transplantation is the most effective and feasible
[67]. Similar to the aforementioned therapies, biocompatible
scaffolds have assisted with delivery. For example, a fibrin
matrix with growth factors can promote the viability and
retention of the cells in the lesion site [68].
After transplantation, stem cell imaging is a useful tool to
determine the therapeutic efficacy. MRI can be used tomoni-
tor the anatomical change of spinal tissue and thus determine
the therapeutic efficacy of SCT [69]. Furthermore, because
many MRI contrast agents have minimal interfere with the
stem cells, MRI can be used to track cells immediately after
transplantation [70]. Although reporter genes seem to be
the most promising and suitable candidate for long-term
monitoring, they are not common for all applications because
of the potential risk of gene alteration. On the other hand,
because bioluminescent imaging uses indirect labels that are
strongly related to the viability and differentiation of the cell,
they are powerful tools for studying the efficacy and safety
of different stem cells in treating spinal cord injury in small
animal models [67] including schemes to evaluate the extent
of tumorigenesis.
Delivery methods of stem cells for treating other organs
or tissues have been widely studied. For instance, stem cell
delivery for knee cartilage repair are either under direct
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injection or arthroscopic surgery with or without additional
scaffolds, growth factors, platelet rich plasma, and gene
therapy [71]. Similarly, direct injection of stem cells and
placing natural or synthetic matrix/scaffolds that contain
stem cells into the periodontium are two main delivery
approaches for periodontal tissue regeneration [72]. For facial
nerve regeneration, stem cells are first prepared into biocom-
patible tubes made of poly(lactic-co-glycolic acid) (PLGA)
or conduits made of chitosan. The tubes and conduits are
later implanted at the injury transection [73]. Nevertheless,
the ideal delivery strategies for various SCT applications
have yet to be determined. Ongoing work will develop
delivery methods that are less invasive with more accurate
and efficient fusion to the damaged tissue with minimal cell
death.
4. Imaging Modalities and
Their Contrast Agents
4.1. Magnetic Resonance Imaging. MRI can provide whole
body, high resolution images by measuring changes of
magnetic field with excellent soft tissue contrast. Spinning
charged nuclei such as hydrogen atoms that have unpaired
protons and neutrons generate magnetic moments that can
be aligned parallel or antiparallel to the longitudinal axes
when an external magnetic field is applied [74]. Subsequently,
while the primary magnetic field remains a radiofrequency
(RF) pulse is applied transversely to align atoms at the
appointed location to the transverse axes. Once the RF energy
is retrieved, the nucleus relaxes back to longitudinal axes
at different speeds due to interactions with environment
known as the spin-lattice relaxation. The relaxation time
is T1. Meanwhile, the exchange of energy between nuceli
disturbs the coherence of procession. The nucleus gradually
processes at different phases at the transverse plane, where
the time for complete out-of-phase relaxation is known as
the spin-spin relaxation time, T2. Different tissues or organs
have various relaxation times and therefore by measuring
the longitudinal and transverse magnetic field, respectively,
the types of tissue are determined [12]. Unlike conventional
imaging modalities, MRI is more favorable because it uses
magnetic field instead of the ionizing radiation. Furthermore,
it has unlimited depth of penetration because of the low
attenuation of the magnetic field in tissue. On the other
hand, it does not show functional, metabolic, and molecular
information. It is also time consuming and costly, which
limits its wide use in clinics and fundamental research.
MRI also is largely limited in its ability to retrieve
functional, metabolic, or molecular information from imag-
ing datasets. However, next generation genes are making
progress in this field [75]. For example, the tyrosinase gene
can promote the production of melanin that can chelate
metal ions [76]. The mms6 bacterial gene is able to uptake
intracellular iron and form cluster of nanoparticle within
and outside the cell membrane [77]. A replication-defective
adenovirus encodingmetalloproteins from the ferritin family
reporter is capable of sequestering endogenous iron from the
organism [75]. Other MRI reporter genes for cell-based can-
cer therapies have been studied and reviewed [78]. However,
these reporter genes have not been fully evaluated in clinical
SCT [74]. Overall, the presence of contrast agent makes
cellular detection possible for MRI and makes it desirable in
tracking grafted stem cells in SCT.
In SCT, appropriate contrast agents help distinguish
and trace transplanted cells in the lesion after the therapy.
There are two types of MRI contrast agent that can strongly
influence T1 relaxation time and T2 relaxation time. The
T1 relaxation time depends on the dipole-dipole interaction
between contrast agent and its surrounding environment.
T1 contrast agents shorten T1 rather than T2. For example,
clinical T1 contrast agents often contain gadolinium (Gd3+)
that has strong paramagnetism because of its seven unpaired
electrons. The relaxation time of water molecule is shortened
when they interact with these unpaired electrons, which
makes the MR signal more intense (Figure 4(d)). These ion
metals can cause cytotoxicity and are usually packaged with
chelates complexes such as 1,4, 7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) [74] or diethylene-triamine
penta-acetic acid (DTPA) [79]. FDA-approved T1 contrast
agents used to image stem cell include Gd-DTPA (Mag-
nevist) [80], Gd chelate gadodiamide (Omniscan) [81], and
Dg-HPDO3A (Prohance) [29]. Labeling stem cells may or
may not need transfection agents [29]. In addition to the
relaxation effect, there is also a magnetic susceptibility effect.
T2 contrast agents (or negative contrast agent) act as a
small magnet and affect T2 relaxation time by introducing
magnetic fields to tissues through water diffusion. Ferro-
magnetic and superparamagnetic iron oxide nanoparticle
(SPION) are typical T2 contrast agents used in the clinic
[29]. In SCT, SPION-labeled stem cells are darker in organs
such as kidney or lymphoid tissues that have intense signal
in MRI [29] (Figure 4(c)). SPIONs have been reported in
some preclinical studies such as cardiac repair [82] and knee
joint repair [83]. Typical commercial SPION contrast agents
include dextran-coated SPION Feridex and carboxydextran-
coated ultrasmall SPION Revosit. These require transfection
agents to be integrated into the cells and these agents have
some toxicity [84]. To address this issue, new SPION contrast
agents such as citrate-SPIONhave been reported to label stem
cell without transfection agent [84, 85]. Furthermore, a recent
report showed that i.v. injected SPIONs can accumulate in the
bone marrow and label stem cells in vivo because of the bone
marrow’s role in the reticuloendothelial system—this is an
important and novel approach to labeling stem cells without
transfection agents [86].
4.2. Nuclear Imaging. Nuclear imaging of SCT can use PET
or SPECT. PET tracers can be produced in a cyclotron. The
mechanisms of contrast are based on emission of a positron
by the PET reporter. These positrons travel through the local
environment where they finally lose kinetic energies and
interact with electrons—this interaction is called annihila-
tion. The change in energy during the annihilation energizes
two 511 keV photons roughly 180∘ from each other [12]. A
gamma ray detector ring, or a set of rings, captures these
photons at 360 degrees and converts electrical or optical
signal from a scintillator to sinogram which is further
reconstructed for tomographic images [12]. Well-known
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Figure 4: MR image of contrast agent labeled stem cells in preclinical models. (a), (b) are images taken before the therapy and (c), (d) are
images taken after the injection of stem cells. Iron oxide nanoparticles were labeled to MSCs and highlighted the cells as darker color pointed
by the arrow in image (c) while Gd3+ nanoparticle highlighted the cells in bright color as shown by the arrow in image (d). LV: left ventricle; Lu:
Lung; LD: lattisimus dorsi; Sh: Shoulder. (a), (c) are reprinted with permission of Wolters Kluwer Health, Inc. [87] and (b), (d) are reprinted
with permission of the American Association for the Advancement of Science [29].
radionuclides include 18F, 64Cu, 111In, and 68Ga [74]. SPECT
tracers produce only one photon, which is generated from
decay of the tracer.
Themost common PET reporter is a small molecule with
high avidity for the glucose-transporter known as 18F-FDG.
18F-FDG is most commonly used in cancer imaging, but
it has also been shown to image stem cells [88]. However,
reporter genes are more common for PET imaging in SCT.
HSV1-tk and its mutants are typical group PET reporter
genes that specifically phosphorylate radioisotopes such as 9-
(4-18F-Fluoro-3-[hydroxymethyl]butyl)guanine (18F-FHBG)
[89] (Figure 5(a)), 2󸀠-18F-fluoro-5-ethyl-1-beta-D-arabino-
furanosyluracil (18F-FEAU) [90], and 131I-2󸀠-fluoro-2󸀠-
deoxy-1-beta-D-arabinofuranosyl-5-iodouracil (131I-FIAU)
[91]. The phosphorylated radioisotopes get entrapped in the
cell.
A protocol of using HSV1-tk and its mutants in tandem
with 18F-FHBG (FDAapproved) has been reported for cancer
imaging [92], and its applications in SCT were reported as
well [14]. Unlike direct labeling with radionuclides such as
111In oxine, the use of HSV1-tk can use a fresh injection
of reporter for each imaging event. This overcomes some
limitations related to radionuclide decay that hampers direct
imaging with PET.
Overall, PET has advantages but also suffers some lim-
itations. PET has high sensitivity at limitless depth of pen-
etration, quantitation capabilities [12], and the ability to
image cell viability via a reporter gene. Importantly, human
reporter genes such as human mitochondrial thymidine
kinase type 2 (hTK2) [93] and human somatostatin receptor 2
(hSSTR2) [94] showed potential to be used in humanwithout
inducing immune response. Furthermore, PET can provide
earlier diagnostics than anatomical technique such as CT and
MRI because it detects biochemical changes which generally
occur before anatomical changes in disease [12]. While
PET imaging does not provide anatomical information, it is
often combined with CT (Figure 5(b)) or MRI to locate the
transplanted cells and understand their location relative to
adjacent anatomy.
SPECT is another nuclear imaging technique for stem
cell tracking, but it uses different radioisotopes and setup.
SPECT uses heavy radioisotopes including 99mTC, 123I, and
111In. SPECT radioisotopes can decay by electron capture.
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Figure 5: PET images of contrast agent-labeled stem cell. Panel (a) is the schematic of the indirect labeling using HSV1-TK and radioisotopes.
Cells are transfected with HSV1-tk via vectors. 18F-FHBG is phosphorylated by the enzyme which is encoded in the gene of the cell, and the
reporter is consequently entrapped in the cell. Reproduced courtesy of Springer Publisher Group [95]. Panel (b) is a PET-CT image of MSCs
that were labeled with a mutant HSV1-tk reporter gene. The cells were implanted into a swine and subsequently administrated with [18F]
FHBG. The PET-CT image provides both anatomical information (gray scale from CT) and the contrast of the implanted cells (color from
PET data). Reproduced courtesy of Radiological Society of North America [96].
The proton in unstable nucleus combines an electron from
the inner shell to form a neutron and emits an electron
neutrino, where simultaneously auger electrons and gamma
ray photons are generated when electrons at outer shell fill
up the inner shell. Generally, SPECT radioisotopes have
a comparably longer half-life than PET radioisotopes, and
thus they are more favorable to those facilities that have
limited ability of on-site cyclotron [97]. They emit photons
at different energies at one angle when the excess protons
decay. To increase the spatial resolution collimators made of
tungsten or lead are placed in front of the gamma camera.
But this also causes low detection efficiency of the photon,
which results in a low sensitivity and a small field of view.
Sodium iodide symporter (NIS) is one of the most widely
studied reporter genes for SPECT, and 123I is used with NIS
for stem cell long-term tracking [98–100]. On the other hand,
in direct labeling, the stem cells can be labeled with the
radioisotopes compounds [101] through incubation for short-
term monitoring of grafted cells. Similar to PET, SPECT has
high sensitivity but lacks anatomical frames and needs to
“cooperate” with other modalities such as CT and MRI.
4.3. Optical Imaging. Optical imaging is a relatively cheap
and easy technique that records the fluorescent or biolu-
minescent signal from samples. Typical technologies are
fluorescence imaging and bioluminescent imaging. Fluo-
rescence requires an optical excitation source—usually a
filtered narrow band light—to excite the contrast agents and
a cooled charged couple device (CCD) camera to receive
the emission photons. Fluorescent contrast agents include
fluorescent protein (e.g., GFP) [102], organic fluorophores
[103, 104] (e.g., indocarbocyanine dye), and quantum dots
[105–107] (e.g., semiconductor nanoparticles). Fluorescent
proteins are indirect labels and fluorophores and quantum
dots are direct labels. Quantum dots have advantages over
organic fluorescent dyes because of their narrow, symmetric
emission, broad excitation, high quantum yield, high molar
extinction coefficient, and exceptional resistance to photo
and chemical degradation [108].
Fluorescent dyes and quantum dots can also be directly
labeled inside or on the cell membrane via peptides (Qtracker
cell labeling kit) or lipid (NeuroTrace lipid tracers). Fluores-
cent imaging has been widely applied in bioimaging research
because of its relatively low cost, capability of multiplexed
imaging, and good temporal resolution [12].These properties
are favorable for tracing stem cells but can also lead to toxicity
(cadmium quantum dots) and autofluorescence [12]. The
main challenge in fluorescent imaging is the lowdepth of pen-
etration caused by the scattering and diffusion of soft tissues.
In larger experiment subjects (larger than mice), the optical
information strongly attenuates in the body and becomes too
weak to be detected before it reaches the detector. Using NIR
fluorescent proteins or fluorophores can alleviate this issue,
but it only increases the optical penetration by millimeters.
Therefore, in SCT, fluorescent imaging is mostly applied in
cellular studies, small animal research, and histology rather
than human clinical trials. Work in the second NIR optical
window is making inroad on this challenging issue [109].
Bioluminescence is an indirect, optical imaging technique
that uses reporter gene to express specific proteins. The
protein (enzyme) reacts with extraneous substrates and
generates photons inside the cell without excitation. A well-
known example is the firefly luciferase that emits photons
by oxidizing D-luciferin in the presence of oxygen, ATP,
and magnesium. Several other luciferase enzymes include
sea pansy luciferase, Renilla reniformis (RLuc), and marine
cope pod luciferase,Gaussia princeps (Gluc) [12, 110–113].The
only setup for bioluminescent imaging is a sensitive camera
(cooledCCD). Similar to fluorescent imaging, the application
of bioluminescence is subjected to the low transmission of
light in body, which limits bioluminescence in the studies
of small animal (Figure 6(b)) and cell culture [74], but
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Figure 6: Optical imaging of transplanted stem cells. (a) In vivo fluorescent images of gastric cancer mouse 10min, 30min, 1 h, 2 h, 4 h, 6 h,
10 h, and 24 h after injection of DiR labeled murine ESCs. Reproduced courtesy of the Ivyspring International Publisher Group [104]. (b)
Bioluminescent image of implanted ESCs in weeks 1, 2, and 4. (b) shows that the luciferase reporter gene is capable of performing long-term
tracking in the migration and viability of implanted cells, which in this case form a teratoma. Reproduced courtesy ofWolters Kluwer Health,
Inc. [114].
bioluminescence does have much lower background signal
than fluorescence and thus is more sensitive.
4.4. Ultrasound Imaging. Ultrasound imaging is not used
as commonly as the other modalities, but it has significant
potential as a real-time, high resolution imaging technique
to guide stem cell delivery. Because sound waves propagate
at different speeds in different tissues, contrast is formed
based on the acoustic impedance at the interface between two
tissues [12]. Ultrasound imaging uses a transducer to send
ultrasonicwaves and receive echoes produced by the interface
[12]. Images are reconstructed by analyzing the amplitude,
frequency, and reflection time interval of the reflected signal
[12]. In cellular imaging, ultrasound imaging is limited to
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(a) (b) (c)
Figure 7: Ultrasound imaging of SCT. Silicon nanoparticles (SiNP) enhance the ultrasound signal of MSCs after cardiac implantation.
Ultrasound resolves the needle catheter and the tissue. As shown in (c), the contrast signal due to the backscatter of SiNP highlights the
implanted cells. Green signal indicates presence of stem cells. Red arrow highlights the bevel of the needle. Reproduced courtesy of the
American Association for the Advancement of Science [29].
the poor contrast. To address this issue, several types of
contrast agents have been developed including microbubbles
[115], silica [116], and gold nanoparticles [56]. Microbubbles
can stably label and highlight cells for minutes after the
delivery [117]. Microbubbles can be controlled and deliver
the cells to the targeted area [118], but due to their micron
size microbubbles are limited to image the cell surface—thus,
they can easily become dissociated from the cells and result
in aberrant signaling.
Nanosize particles made of silica [119] or mesoporous
silica [116] have been developed to overcome this limit and
assist with imaging stem cells in SCT. Ultrasound-guided
transplantation can improve the accuracy of the stem cell
delivery (Figure 7). Ultrasound imaging of stem cells via
reporter genes is quite rare, but genes that produce a cell
surface protein to be imaged with targeted microbubbles has
made this possible [115]. Overall, ultrasound imaging is a
desirable imaging modality due to its advantages such as
relatively inexpensive, high spatial, and temporal resolution,
relatively large depth of penetration, using safe mechanical
waves, and high sensitivity [12]. But it also has limitations
such as a high background signal and poor specificity.
Nevertheless, the ability to obtain anatomical information
and definitive molecular information about the cells makes
it a promising technique.
4.5. Emerging Imaging Modalities. In addition to the afore-
mentioned modalities, there are several modalities gaining
popularities in the research of regenerative medicines. Com-
puted tomography is a clinical imaging technique that gen-
erates three-dimensional images. Regular organs and tissue
are not sensitive to X-ray due to low absorption, but CT can
image stem cells that are labeled with metal contrast agents.
For example, AuNPs coated with glucose have been used to
label MSCs that were imaged with CT after brain implanta-
tion [120]. Ultrashort single-walled carbon nanotubes con-
taining bismuth (bioCl/Bi
2
O
3
) have been used to label pig
MSCs for CT imaging [121]. SPION-labeled (EndoremTM
Iron Oxide NPs) CD133+ stem cells in muscle biopsies show
contrast signal under CT [122]. The primary challenge with
CT-based functional imaging is the low sensitivity of the
technique. Very high cells counts are needed for imagingwith
CT.
Photoacoustic imaging (PAI) compensates for the poor
contrast of ultrasound. The configuration includes a laser
that is able to selectively excite the contrast agent previously
labeled to the stem cell. The heated contrast agent causes
thermoelastic expansion and generates acoustic signal. For
example, gold nanorods can absorb light and are an ideal con-
trast agent for PAI. One of the applications of PAI in SCT is to
provide guidance for accurate stem cell transplantation. PAI-
guided stem cell transplantation using gold-based contrast
agents has been reported [28, 56].
5. Selecting an Imaging Modality
It is important to select an appropriate imaging approach
depending on the application, the experimental subject under
study, the goal of the experiment, and so forth. Fluorescent
imaging and bioluminescent imaging are preferred in the
fundamental research of stem cell cultures, cell sorting
in SCT, and small animal models in preclinical studies
(Figure 6). Bioluminescent imaging can also characterize
stem cells in vivo regarding cell migration and survival in
small animals.
Combining MRI or CT with fluorescent or biolumi-
nescent imaging can provide additional useful anatomical
information. For preclinical studies, each modality is suitable
in certain stage of the therapy: ultrasound or PAI can provide
assistance during the transplantation (Figure 7); MRI is ideal
for checking the lesion before delivery and performing short-
term monitoring of the grafted stem cells (Figure 4); and
using reporter genes in PET/CT or SPECT/CT offers long-
term tracking and can provide quantitative data on cell
viability (Figure 5).
6. Future Developments
Developing biodegradable contrast agents is one of the
future development directions. Degradable contrast agents
can effectively reduce the cytotoxicity and potential toxicity
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by facilitating the clearance of the contrast materials. A
common strategy is conjugating or coating contrast agents
with biodegradable materials. Examples include Gd chelates
conjugated with polyester dendrimers or bovine serum albu-
min for MRI [123, 124], PLGA-encapsulated Lumogen Red
for fluorescent imaging [125], and 99mTc-labeled chitosan
nanoparticles for SPECT [126]. These contrast agents offer
intense contrast signal as well as negligible cytotoxicity or
accumulation in the liver or spleen. Using naturally occurring
materials such as cellulose is another option that minimizes
liver and spleen uptake [127].
Developingmultimodal contrast agents is another impor-
tant trend because SCT requires different imaging modalities
at different stages of the treatment. One example of mul-
timodal imaging is Cerenkov luminescence imaging (CLI)
where the decay of radioisotopes can emitCerenkov radiation
and is captured by sensitive optical detectors. Thus, CLI
can provide deep tissue imaging via the radionuclide as
well as surface-weighted signal. This has been investigated
in small animals [128, 129], but CLI for stem cell tracking
is not common because CLI signal is weak compared to
other detection methods and the emission wavelength (UV-
Vis) is not favorable for in vivomeasurements. Furthermore,
relatively long exposure times are needed to collect a suf-
ficiently high number of optical photons in CLI. However,
CLI has been demonstrated in tracking stem cells with
PET and BLI. Researchers optimized lentiviral vector (LV)
transduction of murine MSCs to obtain multicistronic LVs
that can express firefly luciferase for BLI and hNIS for PET
and CLI [130]. CLI is useful for tracking cells because CLI
allows a relatively cheap and quick acquisition of data and
uses clinical radioisotopes [130].
Multimodal imaging can combine the strength of each
modality for a comprehensive detection. Superficial and deep
penetration imaging can be achieved by combining PAI and
MRI with silica-based nanoparticles [29]. SPECT or PET
uses highly sensitive labels andMRI provides excellent spatial
resolution and thus using a reporter gene with radioisotopes
for viability information with MRI contrast agents for highly
resolved anatomic information can provide short-term and
long-term cell tracking with anatomical information [131,
132]. Combining fluorescent and MRI and using conjugated
fluorescent dye/magnetic particle contrast agents is another
common strategy [133]. In addition, indirect labeling reporter
genes have been demonstrated for multimodality imaging.
For example, a tyrosinase multifunctional reporter gene was
demonstrated to be sensitive in PAI, MRI, and PET [76].
Increasing the viability and differential rate of stem cell
by introducing growth factors such as extracellular matrix
(ECM) or scaffold is a method to strengthen stem cell viabil-
ity. Implanted stem cells usually have short survival time for
many reasons. Extracellular matrix or scaffolds can provide
a microenvironment with structural supports and chemical
stimulations, which facilitates cell activities. This has been
shown both in vitro and in vivo. For example, the decel-
lularized porcine ventricular ECM can effectively support
cardiac progenitor cells by showing a strong serum-induced
proliferation and a resistance to apoptosis in serum starvation
[134]; the poly(ethylene glycol) diacrylate (PEGDA) hydrogel
stimulates the implanted MSCs in cartilage repair and causes
less pain to the patients [135]. Poly-L-lactic acid (PLLA)
scaffolds can prolong the survival and increase the prolif-
eration rate of F3 cells implanted to ablated motor cortex
of the corticectomized rat [136]. Taking advantages of these
extra support structures can improve SCT and increase cell
viability.
Imaging plays an important role in studying the biology
of cancer stem cells (CSCs) as well. It might also influence the
future cancer therapy methodologies such as immunother-
apy, which is a variant of stem cell imaging and SCT. CSCs
might be responsible for cancer development and metastasis
and are also resistant to chemotherapy [137]. Existing cellular
imaging modalities are mature enough to image CSCs [138],
but the focus is how to distinctively label stem-like cells from
the many other nonspecific background cells.
Themost common approach for CSC imaging is to target
unique surface markers on the CSC surface including anti-
body targeting of AC133+ glioblastoma stem cells via PET/CT
[139]. An alternative is tracing CSCs based on their function.
For example, blue lasers can excite the subpopulation of
autofluorescent cells in pancreatic ductal adenocarcinoma,
colorectal carcinoma, hepatocellular carcinoma, and non-
small-cell lung carcinoma [137]. However, surface markers
depend on environment condition, vary in different CSCs,
and cause conflicting data [137], and using intrinsic autoflu-
orescent cells is limited by the low depth of penetration of
optical imaging. Despite this, stem cell imaging is a powerful
tool to help understand the biological behavior of different
types of CSCs and investigate the influence of CSCs in tumor
development and the microenvironment.
7. Conclusion
In this review, we described the important steps in stem cell
imaging including an introduction and comparison of the
imaging modalities and contrast agents as well as a vision
for future developments in the field. Stem cell imaging has
become an indispensable part of SCT. Using the appropriate
imagingmodality ormultiplemodalities can greatly assist the
diagnostics in SCT.
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